Milnacipran versus other antidepressive agents for depression

Cochrane Database of Systematic Reviews

Volumn , Issue 3, 2009, Pages

  Nakagawa, Atsuo ^a   Watanabe, Norio ^b   Omori, Ichiro M ^c   Barbui, Corrado ^d   Cipriani, Andrea ^d   McGuire, Hugh ^e   Churchill, Rachel ^f   Furukawa, Toshi A ^b  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^d UNIVERSITY OF VERONA   (Italy)

^e National Collaborating Centre for Women's and Children's Health   (United Kingdom)

^f UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CLOMIPRAMINE; FLUOXETINE; FLUVOXAMINE; HYPERICUM EXTRACT; IMIPRAMINE; MIANSERIN; MILNACIPRAN; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ACUTE DISEASE; AGITATION; ANXIETY; CLINICAL RESEARCH; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DROWSINESS; DRUG EFFICACY; DRUG MARKETING; DRUG TOLERABILITY; FOLLOW UP; HUMAN; HYPOTENSION; INSOMNIA; MAJOR DEPRESSION; MICTURITION DISORDER; MONOTHERAPY; NAUSEA; REVIEW; SENSITIVITY ANALYSIS; SIDE EFFECT; SOMNOLENCE; SUICIDE ATTEMPT; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VOMITING; XEROSTOMIA;

EID: 70049088284     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006529.pub2     Document Type: Review

References (135)

1. * Ansseau M, von Frenckell R, Mertens C, de Wilde J, Botte L, Devoitille JM, Evrard JL, De Nayer A, Darimont P, Dejaiffe G, Mirel J, Meurice E, Parent M, Couzinier JP, Demarez JP, Serre C. Controlled comparison of two doses of milnacipran (F 2207) and amitriptyline in major depressive inpatients. Psychopharmacology 1989;98(2): 163-168
2. von Frenckell R, Ansseau M, Serre C, Sutet P. Pooling two controlled comparisons of milnacipran (F2207) and amitriptyline in endogenous inpatients. A new approach in dose ranging studies. International Clinical Psychopharmacology 1990;5:49-56.
3. * Ansseau M, Von Frenckell R, Papart P,Mertens C, de Wilde J, Botte L, Devoitille JM, Evrard JL, De Nayer A, Koch-Bourdouxhe S, Darimont P, Lecoq A, Mirel J, Couzinier JP, Demarez JP, Serre C. Controlled comparison of milnacipran (F2207) 200 mg and amitriptyline in endogenous depressive inpatients. Human Psychopharmacology 1989;4:221-227
4. Ansseau M, Von Frenckell R, Serre C, Demarez JP. Controlled comparison of milnacipran (F2207) 200mg and amitriptyline in endogenous depressive inpatients. Therapie 1990;45(3):292.
5. Ansseau M, von Frenckell R, Gerard MA, Mertens C, de Wilde J, Botte L, Devoitille JM, Evrard JL, De Nayer A, Darimont P, Mirel J, Troisfontaines B, Toussaint C, Couzinier JP, Demarez JP, Serre C. Interest of a loading dose of milnacipran in endogenous depressive inpatients. Comparison with the standard regimen and with fluvoxamine. European Neuropsychopharmacology 1991;1(2):113-121
6. Ansseau M, Papart P, Troisfontaines B, Bartholome F, Bataille M, Charles G, Schittecatte M, Darimont P, Devoitille JM, de Wilde J, Dufrasne M, Gilson H, Evrard J-L, De Nayer A, Kremer P, Mertens C, Serre C. Controlled comparison of milnacipran and fluoxetine in major depression. Psychopharmacology 1994;114(1):131-137 (Pubitemid 24150530)
7. Clerc G, Assicot M, Bouchard JM, Cottin M, Guibert M, Liegaut D, Engel P, May JP, Oules J, Pagot R, Patris MF, Ruimy P, Sombret A, Van Amerongen AP, Tournoux A. Antidepressant efficacy and tolerability of milnacipran, a dual serotonin and noradrenaline reuptake inhibitor: A comparison with fluvoxamine. International Clinical Psychopharmacology 2001;16(3):145-151 (Pubitemid 32402359)
8. Endo S, Miura S, Miyasaka M, Yamauchi T, Asai M, Ushijima S, Kamijima K, Hasegawa K, Ogura T. Clinical Evaluation of Milnacipran Hydrochloride, a New Antidepressant for Depression and Depressive State Phase III Clinical Trial with Mianserin Hydrochloride as a Control Drug. Rinsho Hyoka 1995;23(1):39-64.
9. Guelfi JD, Ansseau M, Corruble E, Samuelian JC, Tonelli I, Tournoux A, Pletan Y. A double-blind comparison of the efficacy and safety of milnacipran and fluoxetine in depressed inpatients. International Clinical Psychopharmacology 1998;13(3):121-128 (Pubitemid 28318351)
10. * Lee MS, Ham BJ, Kee BS, Kim JB, Yeon BK, Oh KS, Oh BH, Lee C, Jung HY, Chee IS, Choe BM, Paik IH. A comparison of the efficacy and safety between milnacipran and fluoxetine in the treatment of patients with depression. International Journal of Neuropsy-chopharmacology 2002;5(Suppl 1):205.
11. Lee MS, Ham BJ, Kee BS, Kim JB, Yeon BK, Oh KS, Oh BH, Lee C, Jung HY, Chee IS, Choe BM, Paik IH. Comparison of efficacy and safety of milnacipran and fluoxetine in Korean patients with major depression. Current Medical Research & Opinion 2005;21(9):1369-1375 (Pubitemid 41368568)
12. Leinonen E, Lepola U, Koponen H, Mehtonen OP, Rimon R. Long-term efficacy and safety of milnacipran compared to clomipramine inpatients with major depression. Acta Psychiatrica Scandinavica 1997; 96(6):497-504. (Pubitemid 27519795)
13. Lopez-Ibor JJ, Conesa A, Spanish Milnacipran/Imipramine Study. A comparative study of milnacipran and imipramine in the treatment of major depressive disorder. Current Medical Research and Opinion 2004;20(6):855-860
14. Sechter D, Vandel P, Weiller E, Pezous N, Cabanac F, Tournoux A. A comparative study of milnacipran and paroxetine in outpatients with major depression. Journal of Affective Disorders 2004;83(2-3): 233-236 (Pubitemid 39536200)
15. * Sechter D, Weiller E, Pezous N, Bisserbe JC. Psychomotor retardation is a predictive factor of milnacipran response. International Journal of Neuropsychopharmacology 2000;3(Suppl 1):190.
16. Vandel P, Sechter D, Weiller E, Pezous N, Cabanac F, Tournoux A, Panconi E. Post-treatment emergent adverse events in depressed patients following treatment with milnacipran and paroxetine. Human Psychopharmacology 2004;19(8):585-586 (Pubitemid 40028360)
17. Shinkai K, Yoshimura R, Ueda N, Okamoto K, Nakamura J. Associations between baseline plasma MHPG (3-methoxy-4-hydroxyphenylglycol) levels and clinical responses with respect to milnacipran versus paroxetine treatment. Journal of Clinical Psychopharmacology 2004;24(1):11-17. (Pubitemid 38134160)
18. Tignol J, Pujol Domenech J, Chartres JP, Leger JM, Pletan Y, Tonelli I, Tournoux A, Pezous N. Double-blind study of the efficacy and safety of milnacipran and imipramine in elderly patients with major depressive episode. Acta Psychiatrica Scandinavica 1998;97(2):157-165 (Pubitemid 28145463)
19. Van Amerongen AP, Ferrey G, Tournoux A. A randomised, double-blind comparison of milnacipran and imipramine in the treatment of depression. Journal of Affective Disorders 2002;72(1):21-31. (Pubitemid 35232161)
20. Matsubara R, Onodera I, Ito K, Okada F, Asano Y. A double-blind comparison of milnacipran and imipramine in depressive patients. XXth Collegium Internationale Neuro psychopharmacologicum, Melbourne, Australia. 1996.
21. * Yamashita I, Matubara R, Onodera I, Ito K, Okada K, Asano Y. Clinical evaluation of milnacipran hydrochloride (tn-912) on depression and depressive states -phase iii clinical trial with imipramine hydrochloride as a control drug. Rinsyoiyaku 1995;11(4):819-842
22. Yang JC, Kim SW, Yu BH. Milnacipran versus Sertraline in Major Depressive Disorder: A Double-Blind Randomized Comparative Study on the Treatment Effect and cbeta-Adrenergic Receptor Responsiveness. Korean Journal of Psychopharmacology 2003;14(4): 387-396
23. Baek HK, Kim EJ, Yu BH. The Effect of Antidepressant Treatment on Beta-Adrenergic Receptor Responsiveness in Patients with Major Depression. Korean Journal of Psychopharmacology 2002;13(3):154-163
24. Baek HK, Yu BH. The effect of antidepressant treatment on beta-adrenergic receptor responsiveness in patients with major depression. International Journal of Neuropsychopharmacology 2002;5(Suppl 1): 148.
25. * Dardennes R, Berdeaux G, Bisserbe JC, Lafuma A, Pribil C, Fagnani F. Cost-utility of milnacipran (Ixel(r)) in the prevention of recurrent depression. 11th European College of Neuropsychopharmacology Congress. Paris, France. 31st October 4th November 1998.
26. Dardennes RM, Lafuma A, Fagnani F, Pribil C, Bisserbe JC, Berdeaux G. Economic assessment of a maintenance treatment strategy in prevention of recurrent depressive disorder. Value in Health 2000;3(1): 40-47 (Pubitemid 30232947)
27. Lafuma A, Dardennes R, Fagnani F, Pribil C, Bisserbe JC, Berdeaux G. Clinico-economic assessment of milnacipran in the prevention of depressive episodes. Encephale 1999;25(5):401-407
28. Rouillon F, Berdeaux G, Bisserbe JC, Warner B, Mesbah M, Smadja C, Chwalow J. Prevention of recurrent depressive episodes with milnacipran: consequences on quality of life. Journal of Affective Disorders 2000;58(3):171-180 (Pubitemid 30232773)
29. Rouillon F, Berdeaux G, Chwalow J, Mesbah M. The efficacy of milnacipran (IxelR) in the prevention of recurrent depression: effects on quality of life. 11th European College of Neuropsychopharmacology Congress. Paris, France. 31st October 4th November 1998.
30. Rouillon F, Warner B, Pezous N, Bisserbe JC. Milnacipran efficacy in the prevention of recurrent depression: a 12-month placebo-controlled study. International Clinical Psychopharmacology 2000;15(3): 133-140 (Pubitemid 30326048)
31. Kanemoto K, Matsubara M, Yamashita K, Tarao Y, Inada E, Sekine T. Controlled comparison of two different doses of milnacipran in major depressive outpatients. International Clinical Psychopharmacology 2004;19(6):343-346 (Pubitemid 39506989)
32. Lee MS, Ham BJ, Kee BS, Kim JB, Yeon BK, Oh KS, Oh BH, Lee C, Jung HY, Chee IS, Choe BM, Paik IH. The Efficacy and Safety of Milnacipran in Patients with Major Depression: A comparison with Fluoxetine. Journal of the Korean Neuropsychiatric Association 2004; 43(4):415-424
33. Macher JP, Sichel JP, Serre C, Von Frenckell R, Huck JC, Demarez JP. Double-blind placebo-controlled study of milnacipran in hospitalized patients with major depressive disorders. Neuropsychobiology 1989;22(2):77-82. (Pubitemid 20222993)
34. Shingo N, Kazuhiro S, Keizo Y, Hisashi H, Hitoshi T, Mitsuhiro K, Kenichi I, Tadashi O, Tetsuo S. Gender differences in the clinical effects of fluvoxamine and milnacipran in Japanese major depressive patients. Psychiatry and Clinical Neurosciences 2007;61(4):421-427
35. Onodera I, Asano Y, Ito K, Matsubara R, Okada F. Double-blind controlled comparison of two doses of milnacipran in depressive patients. Clinical Neuropharmacology 1992;15(1 Pt B):418.
36. Wyeth. Phase III multi-center, double-blind, comparative study of Effexor XR for the treatment of depression. controlled-trials.com 2006.
37. Yoshimura R, Mitoma M, Sugita A, Hori H, Okamoto T, Umene W, Ueda N, Nakamura J. Effects of paroxetine or milnacipran on serum brain-derived neurotrophic factor in depressed patients. Progress in Neuropsychopharmacology and Biological Psychiatry 2007;31:1034-1037 (Pubitemid 46824019)
38. Als-Nielsen B, Chen W, Gluud C, Kjaergard LL. Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events?. JAMA 2003 Aug 20;290(7):921-928 (Pubitemid 37430464)
39. Altman DG, Bland JM. Detecting skewness from summary information. BMJ 1996 Nov 9;313(7066):1200.
40. Anderson IM, Nutt DJ, Deakin JF. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines.British Association for Psychopharmacology. Journal of Psychopharmacology 2000 Mar;14(1):3-20.
41. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-III). 3rd Edition. Washington, DC: American Psychiatric Association, 1980.
42. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-III-R). 3rd Edition. American Psychiatric Association, 1987.
43. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). 4th Edition. Washington, DC: American Psychiatric Association, 1994.
44. American Psychiatric Association. Practice guideline for the treatment of patients withmajor depressive disorder (revision). American Psychiatric Association. American Journal of Psychiatry 2000 Apr;157 (4 Suppl):1-45.
45. Appleton KM, Hayward RC, Gunnell D, Peters TJ, Rogers PJ, Kessler D, Ness AR. Effects of n-3 long-chain polyunsaturated fatty acids on depressed mood: systematic review of published trials. American Journal of Clinical Nutrition 2006;84(6):1308-1316 (Pubitemid 44912811)
46. Arroll B, Macgillivray S, Ogston S, Reid I, Sullivan F, Williams B, et al. Efficacy and tolerability of tricyclic antidepressants and SSRIs compared with placebo for treatment of depression in primary care: a meta-analysis. Annals of Family Medicine 2005 Sep-Oct;3(5):449-456 (Pubitemid 41512663)
47. Barbui C, Cipriani A, Brambilla P, Hotopf M. "Wish bias" in antidepressant drug trials?. Journal of Clinical Psychopharmacology 2004 Apr;24(2):126-130 (Pubitemid 38380835)
48. Barbui C, Hotopf M, Freemantle N, Boynton J, Churchill R, Eccles MP, Geddes JR, Hardy R, Lewis G, Mason JM. Selective serotonin reuptake inhibitors versus tricyclic and heterocyclic antidepressants: comparison of drug adherence. Cochrane Database of Systematic Reviews 2007, Issue 3. [DOI: CD002791]
49. Bekelman JE, Li Y, Gross CP. Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA 2003; 289(4):454-465 (Pubitemid 36119966)
50. Bhandari M, Busse JW, Jackowski D, Montori VM, Schunemann H, Sprague S, Mears D, Schemitsch EH, Heels-Ansdell D, Devereaux PJ. Association between industry funding and statistically significant pro-industry findings in medical and surgical randomised trials. Canadian Medical Association Journal 2004 Feb 17;170(4):477-480 (Pubitemid 38293642)
51. Bollini P, Pampallona S, Tibaldi G, Kupelnick B, Munizza C. Effectiveness of antidepressants. Meta-analysis of dose-effect relationships in randomised clinical trials. British Journal of Psychiatry 1999 Apr; 174:297-303. (Pubitemid 29179711)
52. Briley M, Prost J, Moret C. Preclinical pharmacology of milnacipran. International Clinical Psychopharmacology 1996;11(Suppl. 4):9-14.
53. Buchkowsky SS, Jewesson PJ. Industry sponsorship and authorship of clinical trials over 20 years. Annals of Pharmacotherapy 2004 Apr; 38(4):579-585 (Pubitemid 38352217)
54. Chan AW, Hrobjartsson A, Haahr MT, Gotzsche PC, Altman DG. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. JAMA 2004; 291(20):2457-2465 (Pubitemid 38669189)
55. Chan AW, Altman DG. Identifying outcome reporting bias in randomised trials on PubMed: review of publications and survey of authors. BMJ 330;7494:753.
56. Cipriani A, Brambilla P, Furukawa T, Geddes J, Gregis M, Hotopf M, Malvini L, Barbui C. Fluoxetine versus other types of pharmacotherapy for depression. Cochrane Database of Systematic Reviews 2005 Oct 19, Issue 4. [DOI: CD004185]
57. Cipriani A, Furukawa TA, Veronese A, Watanabe N, Churchill R, McGuire HF and Barbui C for the Meta-Analysis of New Generation Antidepressants (MANGA) Study Group. Paroxetine versus other anti-depressive agents for depression. Cochrane Database of Systematic Reviews 2007, Issue 2.
58. Cipriani A, Signoretti A, Furukawa TA, Churchill R, Tomelleri S, Omori IM, McGuire HF and Barbui C for the Meta-Analysis of New Generation Antidepressants (MANGA) Study Group. Venlafaxine versus other anti-depressive agents for depression. Cochrane Database of Systematic Reviews 2007, Issue 2.
59. Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R, Watanabe N, Nakagawa A, Omori IM, McGuire H, Tansella M, Barbui C. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009;373(9665):746-758
60. Cipriani A, La Ferla T, Furukawa TA, Signoretti A, Nakagawa A, Churchill R, McGuire H, Barbui C. Sertraline versus other antidepressive agents for depression. Cochrane Database of Systematic Reviews 2009, Issue 2:CD006117.[Art. No.: CD006117. DOI: 10.1002/14651858.CD006117.pub2] (Pubitemid 351805731)
61. Cipriani A, Santilli C, Furukawa TA, Signoretti A, Nakagawa A, McGuire H, Churchill R, Barbui C. Escitalopram versus other antidepressive agents for depression. Cochrane Database of Systematic Reviews 2009, Issue 2:CD006532.[Art. No.: CD006532. DOI: 10.1002/14651858.CD006532.pub2] (Pubitemid 351805731)
62. Ciuna A, Andretta M, Corbari L, Levi D, Mirandola M, Sorio A, et al. Are we going to increase the use of antidepressants up to that of benzodiazepines?. European Journal of Clinical Pharmacology 2004 Nov;60(9):629-634 (Pubitemid 40064595)
63. Cowen PJ, Ogilvie AD, Gama J. Efficacy, safety and tolerability of duloxetine 60 mg once daily in major depression. Current Medical Research and Opinion 2005;21(3):345-356 (Pubitemid 40490673)
64. Coyne JC, Fechner-Bates S, Schwenk TL. Prevalence, nature, and comorbidity of depressive disorders in primary care. General Hospital Psychiatry 1994 Jul;16(4):267-276 (Pubitemid 24177030)
65. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007;369(9557): 201-207 (Pubitemid 46111014)
66. Ellis P. Australian and New Zealand clinical practice guidelines for the treatment of depression. Australian and New Zealand Journal of Psychiatry 2004 Jun;38(6):389-407. (Pubitemid 39029045)
67. Frampton JE, Plosker GL. Duloxetine : a review of its use in the treatment of major depressive disorder. CNS Drugs 2007;21(7):581-609. (Pubitemid 46991960)
68. Furukawa TA, Guyatt GH, Griffith LE. Can we individualize the 'number needed to treat'? An empirical study of summary effect measures in meta-analyses. International Journal of Epidemiology 2002 Feb;31(1):72-76
69. Furukawa TA, McGuire H, Barbui C. Meta-analysis of effects and side effects of low dosage tricyclic antidepressants in depression: systematic review. BMJ 2002 Nov 2;325(7371):991-995 (Pubitemid 35305144)
70. Furukawa TA, Cipriani A, Barbui C, Brambilla P, Watanabe N. Imputing response rates from means and standard deviations in meta-analysis. International Clinical Psychopharmacology 2005;20(1):49-52. (Pubitemid 40105550)
71. Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta-analyses can provide accurate results. Journal of Clinical Epidemiology 2006 Jan;59(1):7-10. (Pubitemid 41797469)
72. Geddes JR, Freemantle N, Mason J, Eccles MP, Boynton J. SSRIs versus other antidepressants for depressive disorder. Cochrane Database of Systematic Reviews 2000, Issue 2. [DOI: CD001851]
73. Goldstein DJ, Mallinckrodt C, Lu Y, Demitrack MA. Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. Journal of Clinical Psychiatry 2002;63(6):225-231 (Pubitemid 34407082)
74. Greenberg PE, Kessler RC, Birnbaum HG, Leong SA, Lowe SW, Berglund PA, Corey-Lisle PK. The economic burden of depression in the United States: how did it change between 1990 and 2000?. Journal of Clinical Psychiatry 2003 Dec;64(12):1465-1475
75. Greenberg PE, Birnbaum HG. The economic burden of depression in the US: societal and patient perspectives. ExpertOpinion on Pharmacotherapy 2005 Mar;6(3):369-376
76. Guaiana G, Andretta M, Corbari L, Mirandola M, SorioA, D'Avanzo B, Barbui C. Antidepressant drug consumption and public health indicators in Italy, 1955 to 2000. Journal of Clinical Psychiatry 2005 Jun;66(6):750-755
77. Guaiana G, Barbui C, Hotopf M. Amitriptyline versus other types of pharmacotherapy for depression. Cochrane Database of Systematic Reviews 2007, Issue 3. [DOI: CD004186] (Pubitemid 351805731)
78. Guelfi JD, Ansseau M, Corruble E, Samuelian JC, Tonelli I, Tournoux A, Pletan Y. A double-blind comparison of the efficacy and safety of milnacipran and fluoxetine in depressed inpatients. International Clinical Psychopharmacology 1998 May;13(3):121-128 (Pubitemid 28318351)
79. Guy W, Bonato RR. Manual for the ECDEU Assessment Battery.2. Chevy Chase, MD: National Institute of Mental Health, 1970.. Manual for the ECDEU Assessment Battery 2. Chevy Chase, MD: National Institute of Mental Health, 1970.
80. Hamilton M. A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry 1960;23:56-62.
81. Hansen RA, Gartlehner G, Lohr KN, Gaynes BN, Carey TS. Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder. Annals of Internal Medicine 2005 Sep 20; 143(6):415-426 (Pubitemid 41341413)
82. Heres S, Davis J, Maino K, Jetzinger E, Kissling W, Leucht S. Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. American Journal of Psychiatry 2006;163(2):185-194 (Pubitemid 44480836)
83. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003 Sep 6;327(7414):557-560
84. Higgins JP, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5. Chichester, UK: John Wiley & Sons, Ltd., May 2005.
85. Higgins JPT, Altman DG. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 5.01 (updated Sept 2008) www.cochrane-handbook.org. The Cochrane Collaboration, 2008.
86. Higgins JPT, Altman DG. Section 8. Assessing risk of bias in included studies. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 5.01 (updated Sept 2008) www.cochrane-handbook. org. The Cochrane Collaboration, 2008.
87. Imperadore G, Cipriani A, Signoretti A, Furukawa TA, Watanabe N, Churchill R, McGuire HF, Barbui C for the Meta-Analysis of New Generation Antidepressants (MANGA) Study Group. Citalopram versus other anti-depressive agents for depression. Cochrane Database of Systematic Reviews 2007, Issue 2.
88. Ioannidis JP. Indirect comparisons: the mesh and mess of clinical trials. Lancet 2006;368(9546):1470-1472
89. Ito K, Yoshida K, Sato K, Takahashi H, Kamata M, Higuchi H, Shimizu T, Itoh K, Inoue K, Tezuka T, Suzuki T, Ohkubo T, Sugawara K, Otani K. A variable number of tandem repeats in the serotonin transporter gene does not affect the antidepressant response to fluvoxamine. Psychiatry Research 2002;111(2-3):235- 239
90. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, Rush AJ, Walters EE, Wang PS. National Comorbidity Survey Replication. JAMA 2003 Jun 18;289(23):3095-3105
91. Khan A, Khan SR, Walens G, Kolts R, Giller EL. Frequency of positive studies among fixed and flexible dose antidepressant clinical trials: an analysis of the food and drug administration summary basis of approval reports. Neuropsychopharmacology 2003 Mar;28(3):552-557
92. Kupfer DJ, Frank E. Placebo in clinical trials for depression: complexity and necessity. JAMA 2002;287:1853-1854 (Pubitemid 34303631)
93. Lecrubier Y, Pletan Y, Solles A, Tournoux A, Magne V. Clinical efficacy of milnacipran: placebo-controlled trials. International Clinical Psychopharmacology 1996 Sep;11(Suppl 4):29-33. (Pubitemid 26371019)
94. Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 2003 May 31;326(7400):1167-1170 (Pubitemid 36649048)
95. Linde K, Berner MM, Kriston L. St John's wort formajor depression. Cochrane Database of Systematic Reviews 2008, Issue 4.[Art. No.: CD000448. DOI: 10.1002/14651858.CD000448.pub3]
96. Lopez-Ibor J,Guelfi JD, Pletan Y, Tournoux A, Prost JF. Milnacipran and selective serotonin reuptake inhibitors in major depression. International Clinical Psychopharmacology 1996 Sep;11(Suppl 4):41-46 (Pubitemid 26371017)
97. Lu M, Ades T. Combination of direct and indirect evidence in mixed treatment comparison. Statistics in Medicine 2004;23:3105-3124
98. Lu M, Ades T. Assessing evidence consistency in mixed treatment comparisons. Journal of the American Statistical Association 2006; 101:447-459
99. Luborsky L. Clinician's judgments of mental health. Archives of General Psychiatry 1962;7:407-417
100. Lumley S. Network meta-analysis for indirect treatment comparisons. Statistics in Medicine 2002;21:2313-2324.
101. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. British Journal of Psychiatry 1979;134:382-389 (Pubitemid 9136500)
102. Montgomery JH, Byerly M, Carmody T, Li B, Miller DR, Varghese F, Holland R. An analysis of the effect of funding source in randomized clinical trials of second generation antipsychotics for the treatment of schizophrenia. Controlled Clinical Trials 2004 Dec;25(6):598-612. (Pubitemid 39592864)
103. Moret C, Charveron M, Finberg JPM, Couzinier JP, Briley M. Biochemical profile of milnacipran (F 2207), 1-phenyl-1-diethylaminocarbonyl-2-aminomethyl- cyclopropane (Z) hydrochloride, a potential fourth generation antidepressant drug. Neuropharmacology 1985;24:1211-1219 (Pubitemid 16182647)
104. NICE. Depression: management of depression in primary and secondary care (amended). London: National Institute for Health and Clinical Excellence, 2007.
105. Nose M, Cipriani A, Furukawa TA, Omori IM, Churchill R, McGuire HF, Barbui C for the Meta-Analysis of New Generation Antidepressants (MANGA) Study Group. Duloxetine versus other anti-depressive agents for depression. Cochrane Database of Systematic Reviews 2007, Issue 2.
106. Okamura K, Furukawa TA. Remission rates with milnacipran 100mg/day and 150 mg/day in the long-term treatment of major depression. Clinical Drug Investigation 2006;26(3):135-142
107. Omori IM, Watanabe N, Cipriani A, Barbui C, McGuire H, Churchill R, FurukawaTA for the MANGA Study. Fluvoxamine versus other anti-depressive agents for depression. (Protocol). Cochrane Database of Systematic Reviews 2006, Issue 3: CD006114.
108. Oxman AD, Guyatt GH. A consumer's guide to subgroup analyses. Annals of Internal Medicine 1992 Jan 1;116(1):78-84.
109. Papakostas GI, Fava M. A meta-analysis of clinical trials comparing milnacipran, a serotonin-norepinephrine reuptake inhibitor, with a selective serotonin reuptake inhibitor for the treatment of major depressive disorder. European Neuropsychopharmacology 2007;17(1): 32-36 (Pubitemid 44781293)
110. Perlis RH, Perlis CS, Wu Y, Hwang C, Joseph M, Nierenberg AA. Industry sponsorship and financial conflict of interest in the reporting of clinical trials in psychiatry. American Journal of Psychiatry 2005 Oct;162(10):1957-1960 (Pubitemid 41428627)
111. Procyshyn RM, Chau A, Fortin P, Jenkins W. Prevalence and outcomes of pharmaceutical industry-sponsored clinical trials involving clozapine, risperidone, or olanzapine. Canadian Journal of Psychiatry 2004 Sep;49(9):601-606 (Pubitemid 39388352)
112. Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH, Weiss NS. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA 2003;289(19):2533-2544 (Pubitemid 37430155)
113. Puech A, Montgomery SA, Prost JF, Solles A, Briley M. Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: an overview of its antidepressant activity and clinical tolerability. International Clinical Psychopharmacology 1997 Mar;12(2):99-108. (Pubitemid 27286559)
114. Puozzo C, Leonard BE. Pharmacokinetics of milnacipran in comparison with other antidepressants. International Clinical Psychopharmacology 1996 Sep;11(Suppl 4):15-27. (Pubitemid 26371015)
115. Puozzo C, Lens S, Reh C, Michaelis K, Rosillon D, Deroubaix X, Deprez D. Lack of interaction of milnacipran with the cytochrome P450 isoenzymes frequently involved in antidepressant metabolism. Clinical Pharmacokinetics 2005;44:977-978 (Pubitemid 41252846)
116. Salanti G, Higgins JP, Ades A, Ioannidis JP. Evaluation of networks of randomized trials. Statistical Methods in Medical Research 2008; 17:279-301.
117. Santaguida PL, Helfand M, Raina P. Challenges in systematic reviews that evaluate drug efficacy or effectiveness. Annals of Internal Medicine 2005;142(12 Pt 2):1066-1072 (Pubitemid 40847709)
118. Sawada Y, Ohtani H. Pharmacokinetics and drug interactions of antidepressive agents. Nippon Rinsho 2001;59:1539-1545.
119. Sechter D, Vandel P, Weiller E, Pezous N, Cabanac F, Tournoux A, study co-coordinators. A comparative study of milnacipran and paroxetine in outpatients with major depression. Journal of Affective Disorders 2004 Dec;83(2-3):233-236 (Pubitemid 39536200)
120. Smith D, Dempster C, Glanville J, Freemantle N, Anderson I. Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. British Journal of Psychiatry 2002 May;180:396-404. (Pubitemid 34499333)
121. Spencer CM, Wilde MI. Milnacipran. A review of its use in depression. Drugs 1998 Sep;56(3):405-427 (Pubitemid 28454266)
122. Steen A, Den Boer JA. A double-blind sixmonths comparative study of milnacipran and clomipramine in major depressive disorder. International Clinical Psychopharmacology 1997 Sep;12(5):269-281 (Pubitemid 28021754)
123. Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. British Journal of Psychiatry 2001;178:234-241 (Pubitemid 32183606)
124. Walsh BT, Seidman SN, Sysko R, Gould M. Placebo response in studies of major depression: variable, substantial, and growing. JAMA 2002 Apr 10;287(14):1840-1847 (Pubitemid 34303629)
125. Ware JE, Snow KK, Kosinski M, Gandek B. SF-36 Health Survey Manual and Interpretation Guide. Boston,MA: New England Medical Centre, 1993.
126. Watanabe N, Barbui C, Churchill R, Cipriani A, Furukawa TA, McGuire HF, Omori IM for the MANGA Study. Mirtazapine versus other anti-depressive agents for depression (Protocol).. Cochrane Database of Systematic Reviews 2006, Issue 3: CD006528.
127. World Health Organization. The Ninth Revision of the International Classification of Disease and Related Health Problems (ICD-9). World Health Organization, 1978.
128. World Health Organization. The Tenth Revision of the International Classification of Disease and Related Health Problems (ICD-10). World Health Organization, 1992.
129. World Health Organization. The Global Burden of Disease 2004 Update. Geneva: World Health Organization, 2004. [: http://www.who.int/entity/ healthinfo/global-burden-disease/GBD-report-2004update-full.pdf ]
130. WHOQOL Group. The World Health Organization quality of life assessment (WHOQOL): Development and general psychometric properties. Social Science and Medicine 1998;46(12):1569-1665
131. Williams JW, Jr, Mulrow CD, Chiquette E, Noel PH, Aguilar C, Cornell J. A systematic review of newer pharmacotherapies for depression in adults: evidence report summary. Annals of Internal Medicine 2000 May 2;132(9):743-756 (Pubitemid 30244176)
132. Williams JB. Standardizing the Hamilton Depression Rating Scale: past, present, and future. European Archives of Psychiatry and Clinical Neuroscience 2001;251(Suppl 2):II16-12.
133. Wing J.Measuring mental health outcomes: a perspective from the Royal
134. Yoshida K, Ito K, Sato K, Takahashi H, Kamata M, Higuchi H, Shimizu T, Itoh K, Inoue K, Tezuka T, Suzuki T, Ohkubo T, Sugawara K, Otani K. Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2002;26(2):383-386 (Pubitemid 34038069)
135. Zimmerman M, Posternak MA, Chelminski I. Derivation of a definition of remission on Montgomery-Asberg depression rating scale corresponding to the definition of remission on the Hamilton rating scale for depression. Journal of Psychiatric Research 2004;38:577-582 (Pubitemid 39348889)